Implants lower IOP, reduce medication

Article

Implanatation of multiple trabecular micro-bypass implants (iStent, Glaukos) in Schlemm's canal following phamoemulsification successfully and significantly reduced IOP for 12 months after implantation, as well as the number of medications required to maintain target IOP

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
A magnifying glass enhances stocks on a chart. Concept image for global commercialisation agreement, pharmaceutical distribution in eastern and western hemispheres, Europe and EMEA. Image credit: ©Asma – stock.adobe.com

Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop

Martin David Harp
July 23rd 2025
Article

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

A close up of an eye with a brown iris, concept image for diabetic retinopathy and glaucoma research. Image credit: ©Made in Uruguay from Pexels – Canva.com

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001

Sydney M Crago
July 9th 2025
Article

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

A binder labeled "2025 protocol" sits on a pile of papers, graphs and information. Concept image for glaucoma consensus group and interventional glaucoma research findings. Image credit: ©sasirin pamai via Canva.

A new set of guidelines for implementing interventional glaucoma

Hattie Hayes
June 24th 2025
Article

The framework covers ocular hypertension to severe progression

A small icon pinpoints a particular location on a map. Concept image for article titled "pinpointing a first-line treatment for glaucoma." Ophthalmology article, glaucoma laser treatment concept. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Pinpointing a first-line treatment for glaucoma

José María Martínez de la Casa, MD
June 3rd 2025
Article

Laser surgery is an appropriate adjunctive therapy across the continuum of glaucoma care, as well as a safe option for patients who also have cataracts and other complicating factors

An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

Research indicates B vitamins and choline provide neuroprotection against glaucoma

Lynda Charters
May 26th 2025
Article

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

Rethinking race as a risk factor for glaucoma

Rethinking race as a risk factor for glaucoma

M. Roy Wilson, MD, MS
April 9th 2025
Article

Social determinants of health challenge our existing expectations

© 2025 MJH Life Sciences

All rights reserved.